Posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) are common disorders causing significant morbidity and mortality ([@R1],[@R2]). Both are chronic and enduring conditions ([@R3]--[@R6]), with significant impairment in social and occupational functioning, significant incidence of suicide ([@R7]--[@R11]), and high rates of recurrence ([@R12]). PTSD and MDD frequently coexist and share phenomenological, behavioral, and neural circuitry abnormalities. Prior research has shown that MDD occurs in 48% to 69% of individuals with PTSD ([@R3],[@R13]--[@R15]). Likewise, PTSD in the context of MDD often goes unrecognized and might not be appropriately assessed and treated. In addition, patients treated for PTSD may have residual ongoing unrecognized symptoms of depression, both subthreshold and meeting criteria for MDD. Although there remain construct questions with regard to symptom overlap with PTSD and MDD, recent research has shown that these high rates of comorbidity continued to occur even when overlapping symptoms were removed from the diagnoses ([@R15],[@R16]). Therefore, understanding the underlying neural dysfunction across these disorders has the potential to improve identification of occult or residual symptoms. Cognitive problems are especially linked to illness chronicity in PTSD ([@R17]) and have been shown to be particularly difficult to treat in MDD using pharmacotherapy ([@R18]). It has thus been suggested that cognitive problems may be worth tracking across disorders and may be a sensitive marker for early intervention to prevent the onset of illness ([@R19]).

Traditionally, MDD and PTSD have been considered distinct disorders, each with its own psychopathology ([@R20]). Given that many symptoms and biological phenomena overlap between apparently distinct psychiatric disorders and extend between psychiatric patients and the general population, the Research Domain Criteria (RDoC) initiative ([@R21]) has emphasized dimensions of psychopathology, including genes, behaviors, and brain circuits (such as the cognitive control circuit), that are likely to extend across diagnostic categories. Cognitive control has been suggested to "modulate the operation of other cognitive and emotional systems, in the service of goal-directed behavior" ([@R22]), and comprises components including monitoring and implementing control ([@R23]). Cognitive control systems are likely to be a key circuit cutting across diagnostic categories. Depressive symptoms (overlapping with the RDoC "loss" and "frustrated nonreward" dimensions) are a fundamental symptom construct common across multiple psychiatric disorders that in both MDD ([@R24]--[@R27]) and PTSD ([@R24]) are associated with dysfunction within cognitive control regions such as the dorsolateral prefrontal cortex (DLPFC), ventrolateral prefrontal cortex, anterior cingulate cortex, and anterior insula ([@R28]--[@R30]). However, neural substrates of cognitive control have not been investigated in a unified study examining task-induced brain activity across MDD and PTSD, both of which have a high prevalence of depressive symptoms ([@R13]) and cognitive problems ([@R17],[@R18]) but are considered distinct disorders due to distinguishing features ([@R20]).

Cognitive behavioral therapy (CBT) is an effective treatment for both MDD and PTSD, with equally efficacious but more enduring effects than antidepressants for MDD ([@R31]--[@R33]) and with efficacy in PTSD for a variety of trauma types ([@R34],[@R35]). The fact that various mental disorders endorsing elevated depressive symptoms can be alleviated by CBT suggests that common neural mechanisms may be engaged in treatment response. Studies examining neural substrates of CBT have demonstrated changes in cognitive control regions in MDD following treatment ([@R36]--[@R39]) and in PTSD ([@R24],[@R40]--[@R42]). However, there are no published studies investigating neural substrates underlying treatment response to CBT across both MDD and PTSD participants conducted in the same study. For this reason, we studied a sample of both MDD and PTSD participants, all of whom received CBT.

In this study, we tested the overarching hypothesis that symptoms of depression are dimensionally related to circuit-level abnormalities within cognitive control regions across a patient sample including both patients with MDD and those with PTSD and that CBT improves these abnormalities through a common mechanism in both disorders. Specifically, we hypothesized that hypoactivity in cognitive control regions would be remediated by CBT. To test this hypothesis, we used an emotional conflict task ([@R43]) that engages cognitive control to focus attention on either houses or faces and inhibit the response to the other stimulus type. We applied a dimensional cross-disorder analysis on task-induced functional magnetic resonance imaging (fMRI) brain responses to probe neural circuits related to depressive and anxiety symptoms across MDD and PTSD. We predicted that higher levels of depressive symptoms would be associated with decreased brain activation in areas involved in cognitive control in MDD and PTSD at baseline. In secondary analyses, we also evaluated the neural circuitry related to anxiety due to its importance in both MDD and PTSD. Furthermore, we probed the brain mechanisms of CBT in ameliorating cognitive control dysregulation by evaluating task-induced fMRI response before and after treatment. We predicted that CBT would correct such abnormalities similarly across both disorders.

METHODS AND MATERIALS {#S5}
=====================

Participants {#S6}
------------

Our baseline cross-sectional sample consisted of 104 participants: 28 patients diagnosed with MDD, 53 patients diagnosed with PTSD, and 23 healthy control subjects included for comparison ([Figure 1A](#F1){ref-type="fig"}). This full dataset was used to associate the spectrum of depressive symptoms with a continuum of deficits within the cognitive control circuit at time 1. A subset of patients (17 MDD and 34 PTSD) also volunteered for a cognitive behavior therapy treatment trial. Of these, 17 MDD and 27 PTSD participants completed treatment, and 16 MDD and 20 PTSD participants returned for follow-up imaging. Following data exclusions (see [Supplement](#SD1){ref-type="supplementary-material"} for details), a longitudinal imaging sample of 16 patients with MDD, 15 patients with PTSD, and 19 control subjects with usable MRI scans at two time points was included ([Figure 1B](#F1){ref-type="fig"}). (See [Supplement](#SD1){ref-type="supplementary-material"} for the ethnic description.) All participants received their MRI scans at Washington University.

All participants were right-handed, English speaking, and aged 18 to 56 years ([Table 1](#T1){ref-type="table"}). Inclusion diagnosis for MDD and PTSD was established according to DSM-IV-TR Structured Clinical Interview for DSM criteria ([@R44]). All MDD participants had MDD as the primary diagnosis. All PTSD participants had PTSD as the primary diagnosis, and 31.03% had significant depression severity \[defined by Hamilton Depression Rating Scale scores ≥ 17, a standard cutoff for inclusion in trials of MDD ([@R45])\]. PTSD participants had a lifetime mean total score on the Clinician-Administered PTSD Scale of 78.16 ± 18.51. All PTSD participants reported interpersonal violence-based trauma (rape, domestic violence, etc.), usually multiple episodes of long-standing duration. Exclusionary diagnoses by Structured Clinical Interview for DSM criteria included 1) comorbid neurological disorders; 2) current alcohol or substance abuse disorder; 3) history of psychotic disorder, bipolar disorder, anxiety disorder predating MDD or PTSD onset, or obsessive-compulsive disorder; 4) current suicide risk; 5) treatment with any psychotropic or central nervous system--active drug within the previous 3 weeks (5 weeks for fluoxetine); and 6) inadequate MRI scan quality. The initial inclusionary/exclusionary interviews were conducted by Dr. Bruce at the University of Missouri--St. Louis and by Dr. Sheline at Washington University.

We used two scales to measure depression severity. The Hamilton Depression Rating Scale, the most widely used instrument to ascertain depression severity, was used for study inclusion for MDD and, in parallel, to assess depressive symptoms in PTSD at baseline as having significant depression severity ([@R45]). The clinician-administered Montgomery--Åsberg Depression Rating Scale (MADRS), shown to be sensitive to change in symptoms ([@R46]), was used to assess baseline severity and treatment response across diagnoses and over time. Mean baseline MADRS scores were significantly higher in MDD participants (27.4 ± 6.0) than in PTSD participants (19.0 ± 7.9), *t*~70~ = 5.30, *p* \< .001. The Anxious Arousal subscale of the self-report Mood and Anxiety Symptoms Questionnaire (MASQ-AA) ([@R47]) was administered to examine the potential effect of anxiety as compared with depression. Mean baseline MASQ-AA scores did not differ between MDD participants (34.9 ± 12.3) and PTSD participants (32.8 ± 10.8), *t*~43~ = 0.71, *p* = .48. (See [Supplement](#SD1){ref-type="supplementary-material"} for discussion of MASQ-AA choice as the anxiety measure.) Symptom and brain imaging data were always collected on the same day.

For the longitudinal treatment study, patients received 12 weeks of manualized psychotherapy, either CBT for MDD or cognitive processing therapy (CPT) for PTSD, delivered or supervised by the same clinical psychologist (SEB), a highly trained CBT therapist. (See [Supplement](#SD1){ref-type="supplementary-material"} for CBT quality assurance procedures and similarity between CBT and CPT.) Control subjects underwent the same imaging and assessment procedures separated by 12 weeks. All participants provided written informed consent; the Human Subjects Committees of both Washington University and the University of Missouri--St. Louis approved all study procedures.

Emotional Conflict Task {#S7}
-----------------------

In this task, subjects were asked to pay attention to either houses or fearful/neutral faces presented in a target axis (horizontal or vertical, randomized) while ignoring the stimuli presented in the other axis (distractors) ([Supplemental Figure S1A](#SD1){ref-type="supplementary-material"}). This task was designed to probe cognitive control and emotional circuits ([@R43]). (See [Supplement](#SD1){ref-type="supplementary-material"} for further details.)

Image Acquisition {#S8}
-----------------

See [Supplement](#SD1){ref-type="supplementary-material"} for details of image acquisition and preprocessing.

Statistical Analyses {#S9}
--------------------

To study the association between the severity of depressive symptoms and the level of brain dysfunction, we fit voxelwise linear mixed-effects (LME) models (using the nlme package in R) ([@R48]) on task activation data across all participants (control, MDD, and PTSD). We included all participants instead of patients only because MADRS scores were continuous across healthy and patient populations ([Figure 1A](#F1){ref-type="fig"}), although for depressed participants there were no MADRS scores \< 18. This dimensional approach allowed us to characterize a more complete spectrum of depressive symptoms. Thus, our LME model included fixed-effect terms for MADRS, task condition (a categorical variable with four levels), MADRS by condition interaction, age, gender, education, and head motion (mean relative displacement) to estimate their associations with brain activation. A random intercept term was included in the model to account for within-subject correlations among the repeated measures. (See [Supplement](#SD1){ref-type="supplementary-material"} for anxiety analyses.)

For the analysis of the longitudinal impact of CBT, we used voxelwise LME modeling and conducted voxelwise analyses within the whole brain. We first tested for a group by time interaction and then assessed activation in patients to identify brain regions that changed significantly after treatment. Specifically, fixed effects included treatment (as an indicator for pre-CBT vs. post-CBT), task condition, task condition by treatment interaction, age, gender, and head motion; a random effect for subject was also included. For clusters identified in this voxelwise analysis, we extracted the region of interest (ROI) means in patients and control subjects at baseline and at 12 weeks. For patients, a post hoc comparison was performed to illustrate the treatment effect divided by diagnosis (MDD vs. PTSD). For control subjects, paired-sample *t* tests were performed within these a priori defined areas to test for time and practice effects. (See [Supplement](#SD1){ref-type="supplementary-material"} for within-subject analyses in control subjects.) For brain regions showing significant changes in patients following CBT (but not in control subjects), we computed partial correlations (controlling for age, sex, and motion) between change scores of activation and behavioral measures, either depressive symptoms or task reaction time (RT). Both change in symptoms and task RT were quantified using a normalized score defined as 100 × (postCBT − preCBT)/preCBT.

For voxelwise analyses, multiple comparisons were corrected using Gaussian random field theory ([@R49]) (easythresh command implemented in FSL). We used a cluster-defining threshold of *Z* \> 3.09 because recent work has emphasized that lower thresholds are subject to a higher risk of type I error. Ecklund *et al.* ([@R50]) showed that a cluster threshold of *Z* \> 3.09 produced type I error rates that were close to the nominal familywise error rate of alpha = .05, whereas a more liberal threshold of *Z* \> 2.33 resulted in familywise error rates of 10% to 50%.

RESULTS {#S10}
=======

Task Performance and Clinical Symptom Scales {#S11}
--------------------------------------------

At baseline, patients (78.84 ± 12.89%) and healthy controls (78.58 ± 11.57%) did not differ significantly in average performance accuracy (*p* \> .20). (See [Supplement](#SD1){ref-type="supplementary-material"} for further details.) A repeated-measures analysis of variance revealed that there was no significant group effect (patients vs. controls) or group by task condition interaction on RT for correct trials (*p* \> .20). After 12 weeks, RT was significantly decreased in patients following CBT (*t*~30~ = 2.75, *p* = .01, *d* = 0.51) but not in healthy control subjects (*p* \> .20). After treatment, patients' depressive symptoms assessed by MADRS were also significantly improved (*t*~30~ = −6.15, *p* \< .001, *d* = 1.12; mean reduction relative to baseline: 66.31%). Following treatment, mean MADRS scores did not differ between MDD participants (7.0 ± 7.5) and PTSD participants (6.8 ± 6.7), *t*~29~ = 0.08, *p* = .94. In addition, mean MASQ scores did not differ between MDD participants (25.1 ± 9.5) and PTSD participants (23.2 ± 5.4), *t*~21~ = 0.60, *p* = .52. Importantly, the improvement in depressive symptoms was significantly correlated with improvement in RT (partial *r* = .42, *p* = .02, *n* = 30, controlling for age and gender), with greater symptom improvement associated with greater reductions in RT ([Figure 2](#F2){ref-type="fig"}).

Correlations Between Task Activity and Depressive and Anxiety Symptoms in MDD and PTSD {#S12}
--------------------------------------------------------------------------------------

Correlations between task activity and depressive symptoms were assessed using baseline data. Because no interaction effect was found to be significant (symptom by task condition), the interaction term was dropped from the model. Thus, symptom score and task condition were kept in the model as main effects only. We found that the activation of the left DLPFC (center of mass in Montreal Neurological Institute coordinates: *x* = −45, *y* = 34, *z* = 17) was negatively correlated with MADRS scores across all participants (*r* = −0.40, *p* \< 0.001, *n* = 95) ([Figure 3A](#F3){ref-type="fig"}), and this brain--symptom association did not differ between patients with MDD and those with PTSD (*p* \> .20). The similarity in brain--symptom association between MDD and PTSD was not driven by comorbid depression status among patients with PTSD (see [Supplemental Figure S2](#SD1){ref-type="supplementary-material"}) given that similar results were obtained after excluding the patients with PTSD with higher depressive symptom scores (Hamilton Depression Rating Scale ≥ 17) (*p* \> .20). This similarity was also not dependent on including the control subjects (see [Supplemental Figure S2](#SD1){ref-type="supplementary-material"}). Because depression and anxiety symptoms were correlated (*r* = .55, *p* \< .001), we also examined the correlation between depressive symptoms and brain activation within clusters identified in the main analyses after controlling for MASQ-AA scores. A strongly overlapping cluster located within the left DLPFC (center of mass in Montreal Neurological Institute coordinates: *x* = −46, *y* = 35, *z* = 17) was negatively correlated with MADRS scores (*r* = −.40, *p* \< .001, *n* = 95) ([Figure 3B](#F3){ref-type="fig"}). This specificity analysis allowed us to examine the unique variance explained by depression after controlling for anxiety. We also examined the effect of anxiety without ([Figure 3C](#F3){ref-type="fig"}) and with ([Figure 3D](#F3){ref-type="fig"}) controlling for depression. (See [Supplemental Results](#SD1){ref-type="supplementary-material"} for the analysis of anxiety symptom correlation with brain activity.)

Increased Activation Within the Cognitive Control System Following CBT {#S13}
----------------------------------------------------------------------

Although trending toward greater increase in patients (see [Supplemental Figure S4](#SD1){ref-type="supplementary-material"}), no time by group interactions survived correction for multiple comparisons in the longitudinal data analysis. We did, however, identify 14 clusters showing significant changes in patients following CBT in the within-group analyses. These clusters included the bilateral inferior frontal gyrus/anterior insula, right middle frontal/precentral gyrus, left precentral gyrus, dorsal anterior cingulate, middle cingulate, precuneus, thalamus/brain stem, striatum, and various visual areas ([Figure 4](#F4){ref-type="fig"} and [Supplemental Table S1](#SD1){ref-type="supplementary-material"}). [Supplemental Figure S5](#SD1){ref-type="supplementary-material"} shows the fMRI activity of patients split by MDD versus PTSD diagnosis. ROI-based analyses on these clusters in healthy control subjects revealed that none showed significant changes from time 1 to time 2. Although CBT was associated with improved symptoms and enhanced activity in cognitive control areas, no significant correlations were found between these changes in brain activation and changes in depressive symptoms (*p* \> .20). (See [Supplement](#SD1){ref-type="supplementary-material"} for longitudinal brain activity changes in controls and comparison of patients who were vs. were not included in the longitudinal study.)

DISCUSSION {#S14}
==========

In this study, we extended the investigation of depressive and anxiety symptoms to a transdiagnostic task-based study in MDD and PTSD in the context of CBT, a standardized and highly evidence-supported therapy. We found that DLPFC activity at baseline was related to depressive symptoms, even after controlling for anxiety. We also found that anxiety symptoms at baseline were related to DLPFC activity; however, this relationship did not survive after controlling for depressive symptoms. Furthermore, following CBT, patients had statistically significant increases in activation in multiple cognitive control regions, including bilateral ventrolateral prefrontal cortex/anterior insula, middle frontal gyrus, DLPFC, dorsal anterior cingulate, striatum, and thalamus. These results support the need for additional RDoC ([@R21]) style analyses across disorders and treatment modalities to better inform diagnostic nosology and to understand common mechanisms of treatment action.

Dimensional Representations of Depression {#S15}
-----------------------------------------

Using the same task paradigm, previous work has demonstrated abnormal cross-sectional fMRI blood oxygen level--dependent responses for either patients with MDD ([@R51]) or patients with PTSD ([@R52]) within cognitive control circuitries. Here, we built on these prior results by examining the relationship between task activation and dimensional severity of depression across diagnostic categories. The observed associations between depressive symptoms and DLPFC activation during this task are consistent with meta-analyses that have reliably implicated hypoactivity of the DLPFC in depression ([@R24],[@R27]) and have found that various forms of successful treatments remediate this hypoactivity ([@R26],[@R33]). The relationship between depressive symptoms and DLPFC hypoactivation was present in the PTSD group, which is particularly relevant given that it is common for patients with PTSD to endorse elevated depressive symptoms and frequently to have a comorbid clinical MDD diagnosis ([@R13]). Notably, this dimensional relationship between activation and depression severity was present regardless of whether patients with PTSD had high depression severity, suggesting that even lower levels of depression affect this circuitry in patients. Thus, our data support a common neural signature associated with depression across MDD and PTSD.

Psychotherapy Processes Across Disorders {#S16}
----------------------------------------

It is now well established that CBT reduces depressive symptom severity with large effect sizes for MDD and PTSD examined separately ([@R53]). The neural mechanisms of CBT have been extensively examined in MDD \[for reviews, see ([@R33],[@R38])\] and also in PTSD \[for reviews, see ([@R24],[@R42])\]. For example, increased activity in lateral prefrontal cortex following CBT has been seen in MDD ([@R33]) but has not been similarly evaluated in a dimensional study examining both MDD and PTSD together. Among patients with PTSD, DLPFC task activation extending into the inferior/ventrolateral prefrontal cortex has been shown to predict reductions in PTSD symptoms following selective serotonin reuptake inhibitors treatment ([@R54]). Given that CBT is an effective treatment for both disorders, the disorders themselves may have a common underlying abnormality that responds to CBT. Our data suggest that there may be a neural representation of this common element of clinical response. Consistent with an RDoC approach emphasizing dimensions that cut across clinical disorders, we found symptom overlaps across disorders and similar brain changes ([Supplemental Figure S5](#SD1){ref-type="supplementary-material"}) in response to CBT treatment across disorders. This is further supported by our finding that amelioration in symptoms was correlated with improvement in task performance across diagnoses.

Reciprocally connected prefrontal cortical regions together with the dorsal anterior cingulate cortex, posterior parietal lobe, thalamus, and striatum have long been described as forming a cognitive control network. This network has been associated with active goal planning and maintenance ([@R55]), behavioral inhibition, task flexibility/cognitive control ([@R56]), and reorienting attention ([@R57]). Prominent studies have identified dissociable neural components of cognitive control in monitoring cognitive control (more associated with anterior cingulate activity) and implementing cognitive control (more associated with DLPFC activity) ([@R23]). Thus, given the primary association between decreased DLPFC activity and depressive symptoms at baseline, it may be that an inability to exert cognitive control could be implicated in the association of DLPFC hypoactivity with depression. A growing number of studies report alterations of this control system across a striking range of mental disorders, suggesting a critical role for the control system in promoting and maintaining mental health ([@R58],[@R59]). An influential theory of the neural mechanisms of psychotherapy suggests that successful treatment of depression is associated with increased activity in control system regions and decreased activity in amygdala and other emotional processing regions ([@R33],[@R60]). Consistent with this theory, the flexible hub theory also suggests that CBT may enhance the control system by augmenting its feedback control mechanism and promoting the cognitive flexibility necessary for psychotherapy to be effective ([@R58]). Using the same task, we previously found ([@R51]) that subjects with depression had amygdala and subgenual anterior cingulate cortex hyperactivity in addition to DLPFC hypoactivity. However, that study defined a priori ROIs. In the current study, we used a data-driven approach that identified DLPFC hypoactivity across a spectrum of MDD and PTSD participants. In addition, we previously ([@R61]) found a treatment effect of medication that was associated with increased DLPFC hypoactivity and decreased amygdala hyperactivity in a priori defined ROI. In contrast, the current work focused on the treatment effect of CBT in a data-driven approach that is transdiagnostic.

Our prediction that anxiety symptoms would be independently associated with brain activity abnormalities was not borne out by the data. Whereas regressing out anxiety symptoms did not change the correlation of MADRS with DLPFC activity, the converse was not true; regressing out depression scores removed the association of MASQ-AA with DLPFC activity. In part, this may have been due to a restricted range of MASQ-AA scores. (See [Supplement](#SD1){ref-type="supplementary-material"} for further discussion of anxiety symptoms in PTSD survivors with multiple traumas.)

Limitations {#S17}
-----------

Our PTSD population mainly included female interpersonal violence survivors, and thus further studies of PTSD resulting from other traumatic events and including men would be necessary to determine the generalizability of our findings. While there was a correlation between improvement in symptoms and task performance, we did not see an association between symptom change and changes in brain activity after treatment, suggesting that the degree of cognitive control function enhancement following CBT might not be related to depressive symptoms in a simple linear fashion. It is possible that our sample size was not sufficient to capture these associations or that the relationship between symptom improvement and brain alteration was too complex to be captured by the current regression model. Therefore, understanding mechanisms of CBT will also require further nuanced approaches to dismantle constituent processes of the treatment and to link them more tightly to task probes of specific cognitive/affective functioning in the scanner. In this regard, lack of a placebo patient control group limits our interpretation of brain changes as purely CBT induced. We did not find any significant interaction effects between time and group (patients vs. control subjects) in the longitudinal analysis. However, we believe that the changes observed in patients in cognitive control brain regions are likely attributable to more than just time or practice effects because the control subjects studied across the same time span did not show significant brain activity changes in these regions. Another possibility that must be considered is that the effects of repeat testing could be baseline dependent (e.g., easier to see an increase when the initial activity was reduced). The significance of the increase in task-related cognitive control region activation is intriguing. It could be that these changes are a consequence of CBT/CPT, signifying broadly enhanced top-down control that may influence psychiatric health indirectly through improved coping behaviors but having no direct relationship with degree of symptom changes.

Our investigation of treatment effects was performed in a relatively large number of unmedicated patients, which might not be representative of the usual medicated patient population. However, this could also be a strength of the research study because getting such a sample is unusual and it aids in interpretability of brain imaging findings. Larger samples of patients with PTSD with less depressive symptom endorsements, although less representative of the typical patient with PTSD, might be used in future studies to determine unique PTSD brain features and processes. Finally, the lack of interaction with emotion type (fear/neutral) in our imaging data may be due to the known inconsistencies in the depression literature with eliciting hyperresponse to aversive stimuli in MDD ([@R62]). Our results suggest that perhaps the system affected by MDD and PTSD and most responsive to psychotherapeutic treatment in both disorders is the cognitive control system, which (as we discussed above) is not a single unitary construct but rather has several distinct constituents.

Implications {#S18}
------------

Our results suggest that abnormalities in the activation of cognitive control regions across MDD and PTSD are associated with symptoms of depression. Furthermore, we provided evidence that activation of cognitive control regions is similarly enhanced following treatment with CBT in both MDD and PTSD. These results accord with the RDoC conceptualization of mental disorders and implicate improved cognitive control activation as a transdiagnostic mechanism for CBT treatment outcome.
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![Participant characteristics. **(A)** Distribution of Montgomery--Åsberg Depression Rating Scale (MADRS) scores for the cross-sectional sample by diagnostic group. **(B)** Flowchart of the longitudinal subsample. HC, healthy control subjects; MDD, patients with major depressive disorder; PTSD, patients with posttraumatic stress disorder.](nihms957832f1){#F1}

![Change in depression severity and reaction time (RT) with cognitive behavioral therapy (CBT). **(A, B)** Montgomery--Åsberg Depression Rating Scale (MADRS) scores **(A)** and task RT **(B)** were significantly decreased at time 2 following CBT in patients (PAT). Healthy control subjects (HC) did not change. The percentage change of RT is plotted against the percentage change of the MADRS in **(C)**. % Change is defined as (PostCBT − Baseline)/Baseline × 100. \**p* \< .05; \*\*\**p* \< .005.](nihms957832f2){#F2}

![Activation in cognitive control regions correlates with depression severity across major depressive disorder (MDD) and posttraumatic stress disorder (PTSD) groups at baseline. **(A)** Brain regions showing significant correlation with Montgomery--Åsberg Depression Rating Scale (MADRS) scores are shown in axial slice view in Montreal Neurological Institute coordinates (*Z* \> 3.09, *p* \< .05, Gaussian random field theory corrected). The cluster mean activations were plotted against the baseline MADRS scores across all subjects. **(B)** Brain regions showing significant correlation with MADRS scores after regressing out Anxious Arousal subscale of Mood and Anxiety Symptoms Questionnaire (MASQ-AA) scores are shown in axial slice view in Montreal Neurological Institute coordinates (*Z* \> 3.09, *p* \< .05). The residual activation and MADRS scores computed after regressing out MASQ-AA scores were plotted against each other. **(C)** Brain regions showing significant correlation with MASQ-AA scores are shown in axial slice view in Montreal Neurological Institute coordinates (*Z* \> 3.09, *p* \< .05, Gaussian random field theory corrected). The cluster mean activations were plotted against the baseline MASQ-AA scores across all subjects. **(D)** Brain regions showing significant correlation with MASQ-AA scores after regressing out MADRS scores. DLPFC, dorsolateral prefrontal cortex. HC, healthy control subjects.](nihms957832f3){#F3}

![Longitudinal change in activation following cognitive behavioral therapy in patients. Brain regions where the activation during the conflict task exhibited significant increases (*Z* \> 3.09, *p* \< .05, Gaussian random field theory corrected) following cognitive behavioral therapy (CBT) in patients (PAT) with major depressive disorder or posttraumatic stress disorder are shown on a surface map using BrainNet Viewer ([@R63]) and in slice view in Montreal Neurological Institute coordinates. Region of interest mean activation of the 14 clusters showing significant increase in patients following cognitive behavioral therapy treatment are plotted for patients and healthy control subjects (HC) at baseline and at 12 weeks (see [Supplemental Table S1](#SD1){ref-type="supplementary-material"} for spatial location of these clusters). None of these clusters showed significant change at 12 weeks in HC. \**p* \< .05; \*\*\**p* \< .005. B, bilateral; dACC, dorsal anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex; IFG/aIns, inferior frontal gyrus/anterior insula; L, left; MCC, middle cingulate cortex; R, right.](nihms957832f4){#F4}

###### 

Participant Demographic, Clinical, and Behavioral Information

                             Cross-sectional Sample (*n* = 104)   Longitudinal Subsample at 12 Weeks (*n* = 50)                                                                                    
  -------------------------- ------------------------------------ ----------------------------------------------- -------------------------- -------------------------- -------------------------- --------------------------
  Sample Size, *n*           23                                   53                                              28                         19                         15                         16
                                                                                                                                                                                                   
  Gender, Male/Female, *n*   4/19                                 0/53                                            6/22                       4/15                       0/15                       2/14
                                                                                                                                                                                                   
  Age, Years (SD)            32.6 (9.55)                          32.5 (9.72)                                     33.9 (8.27)                33.4 (10.1)                32.9 (11.7)                34.6 (8.29)
                                                                                                                                                                                                   
  Education, Years (SD)      17.2 (2.82)                          14.9 (3.02)                                     15.3 (2.15)                17.3 (2.94)                15.2 (1.47)                15.1 (2.31)
                                                                                                                                                                                                   
  \% on Psychotropics        N/A                                  0                                               0                          N/A                        0                          0
                                                                                                                                                                                                   
  MADRS, Mean (SD)           1.38 (2.03) \[*n* = 16\]             19.0 (7.93) \[*n* = 51\]                        27.4 (5.95) \[*n* = 28\]   1.11 (2.42) \[*n* = 13\]   6.80 (6.71) \[*n* = 15\]   7.00 (7.47) \[*n* = 16\]
                                                                                                                                                                                                   
  CAPS_m, Mean (SD)          N/A                                  67.8 (16.1) \[*n* = 52\]                        N/A                        N/A                        21.2 (11.6) \[*n* = 14\]   N/A
                                                                                                                                                                                                   
  MASQ-AA, Mean (SD)         20.2 (3.57) \[*n* = 20\]             32.8 (10.8) \[*n* = 51\]                        34.9 (12.3) \[*n* = 25\]   19.9 (3.03) \[*n* = 16\]   23.2 (5.44) \[*n* = 14\]   25.1 (9.54) \[*n* = 13\]
                                                                                                                                                                                                   
  Accuracy, % (SD)           78.6 (11.6)                          77.4 (14.1)                                     81.6 (9.92)                73.9 (26.7)                83.1 (8.26)                75.6 (24.3)
                                                                                                                                                                                                   
  Reaction Time, ms (SD)     811.14 (208.63)                      831.86 (177.63)                                 851.80 (202.03)            778.90 (190.22)            789.00 (166.59)            759.63 (169.65)

CAPS_m, Clinician-Administered PTSD Scale past-month total; HC, healthy control subjects; MADRS, Montgomery--Åsberg Depression Rating Scale; MASQ-AA, Anxious Arousal subscale of Mood and Anxiety Symptoms Questionnaire; MDD, patients with major depressive disorder; N/A, not applicable; PTSD, patients with posttraumatic stress disorder.
